Cumming Capital

Wade E. Cumming is the principal and ultimate decision-maker, per public record. The firm has not publicly named a chief investment officer or investment committee, which is consistent with a closely held single-family office where the wealth creator retains control over capital allocation.

The wealth originates from the pharmaceutical sector. Wade Cumming founded Nephron Pharmaceuticals, a manufacturer of generic respiratory medications and a provider of outsourced sterile compounding services. The subsequent sale of the company's active pharmaceutical ingredient division crystallized the liquidity that funds the family office.

The portfolio appears concentrated in healthcare and life sciences — sectors aligned with the principal's operational background — alongside real estate holdings. The firm does not publicly disclose full asset-class allocations, but the healthcare focus is a logical extension of Wade Cumming's career building a pharmaceutical manufacturing business.

No. All available evidence indicates Cumming Capital operates strictly as a single-family office managing the Cumming family's own capital. There is no indication the firm accepts external limited partners or provides wealth management services to other families.

Deal flow likely combines the principal's deep healthcare network — built over decades in pharmaceutical manufacturing and medical supply chains — with the firm's physical presence in four U.S. cities. The Salt Lake City and San Francisco offices provide coverage of two distinct life sciences ecosystems, while Chicago and Sandy anchor more traditional middle-market private equity and real estate origination.